Menu Search
Equities

Ajanta Pharma Ltd

AJANTPHARM:NSI

Ajanta Pharma Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,960.05
  • Today's Change14.55 / 0.49%
  • Shares traded57.30k
  • 1 Year change+54.26%
  • Beta0.1611
Data delayed at least 15 minutes, as of Nov 22 2024 10:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy2
Outperform4
Hold1
Sell1
Strong Sell2

Share price forecast in INR

The 10 analysts offering 12 month price targets for Ajanta Pharma Ltd have a median target of 3,034.00, with a high estimate of 3,665.00 and a low estimate of 1,981.00. The median estimate represents a 2.40% increase from the last price of 2,963.00.
High23.7%3,665.00
Med2.4%3,034.00
Low-33.1%1,981.00

Dividends

In 2024, Ajanta Pharma Ltd reported a dividend of 10.00 INR, which represents a 42.86% increase over last year. The 7 analysts covering the company expect dividends of 18.90 INR for the upcoming fiscal year, an increase of 89.00%.
Div growth (TTM)42.86%
More ▼

Earnings history & estimates in INR

On Oct 28, 2024, Ajanta Pharma Ltd reported 2nd quarter 2025 earnings of 17.26 per share. This result was in line with the expectation of the one analyst following the company and exceeded last year's 2nd quarter results by 11.35%.
The next earnings announcement is expected on Jan 29, 2025.
Average growth rate+3.46%
Ajanta Pharma Ltd reported annual 2024 earnings of 64.77 per share on May 02, 2024.
Average growth rate+18.34%
More ▼

Revenue history & estimates in INR

Ajanta Pharma Limited had 2nd quarter 2025 revenues of 11.87bn. This bettered the 11.32bn consensus of the 6 analysts covering the company. This was 16.22% above the prior year's 2nd quarter results.
Average growth rate+3.77%
Ajanta Pharma Limited had revenues for the full year 2024 of 42.09bn. This was 12.45% above the prior year's results.
Average growth rate+12.94%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.